French Innovative Leukemia Organisation
Quick facts
Marketed products
- Xospata · Oncology
Phase 3 pipeline
- Experimental (fludarabine) · Oncology
Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. - Lomustine, intermediate dose cytarabine · Oncology
This combination uses lomustine (a nitrosourea alkylating agent) and intermediate-dose cytarabine (a nucleoside antimetabolite) to damage cancer cell DNA and inhibit DNA synthesis. - MINI CHEP · Oncology
MINI CHEP is a chemotherapy regimen combining mini-dose chemotherapy agents designed to treat acute leukemia with reduced toxicity.
Phase 2 pipeline
- ACA Continuation · Oncology
ACA Continuation works by continuing the effects of ACA. - Adriblastin · Other
- alkeran · Oncology
- CEEP regimen · Oncology
CEEP regimen is a combination of chemotherapy drugs used to treat acute lymphoblastic leukemia. - Cytarabine-Idarubicin Association
- Cytarabine-Venetoclax Association · Oncology
Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells. - Doxorubicin pegylated
- Doxorubicine pegylated
- First line therapy
- RiBVD
- Ruxolotinib · Other
- Stop ACA
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: